Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
BerGenBio ASA
Alaunos Therapeutics
Celltrion
Novartis
Novartis
Novartis
Cantargia AB
Novartis
MacroGenics
Bayer
Novartis
Novartis
Morphotek
Lumos Pharma
Geneplus-Beijing Co. Ltd.
Novartis
Bayer
Hoffmann-La Roche
Esanex Inc.
Endocyte
AstraZeneca
Axelar AB
Pharmacyclics LLC.